| Cas Number: | 1398568-47-2 |
| Pubchem: | 73297272 |
| Iuphar Ligand: | 12941 |
| Drugbank: | DB15257 |
| Unii: | R3I80TLN7S |
| Kegg: | D12621 |
| Chembl: | 4292264 |
| Synonyms: | DS-3032 |
| C: | 30 |
| H: | 34 |
| Cl: | 2 |
| F: | 1 |
| N: | 5 |
| O: | 4 |
| Smiles: | CC1(CCC2(CC1)[C@@]3([C@H]([C@@H](N2)C(=O)N[C@@H]4CC[C@H](OC4)C(=O)N)C5=C(C(=NC=C5)Cl)F)C6=C(C=C(C=C6)Cl)NC3=O)C |
| Stdinchi: | 1S/C30H34Cl2FN5O4/c1-28(2)8-10-29(11-9-28)30(18-5-3-15(31)13-19(18)37-27(30)41)21(17-7-12-35-24(32)22(17)33)23(38-29)26(40)36-16-4-6-20(25(34)39)42-14-16/h3,5,7,12-13,16,20-21,23,38H,4,6,8-11,14H2,1-2H3,(H2,34,39)(H,36,40)(H,37,41)/t16-,20+,21+,23-,30-/m1/s1 |
| Stdinchikey: | RYAYYVTWKAOAJF-QISPRATLSA-N |
Milademetan is an investigational new drug that is being evaluated to treat liposarcoma.[1] It is a MDM2 inhibitor.[2]